prof. David Creytens (MD, PhD)

CRIG group leader
David Creytens

Pathologist, Head of Clinics, Department of Pathology (UZ Gent)
Associate Professor UGent, Department of Medical and Forensic Pathology (Faculty of Medicine and Health Sciences, UGent)
Professor of Soft Tissue and Bone Pathology, UGent and UZ Gent
Member of the Education Committee Medicine UGent


Research focus

Prof. David Creytens is a clinician scientist / pathologist with a special interest and expertise on bone and soft tissue tumors. His clinical focus includes evaluating histologic and immunohistochemical parameters that predict clinical outcome, and identifying diagnostic and prognostic biomarkers in sarcomas. His aim is to crosslink patient care (diagnostic pathology of bone and soft tissue tumors) with basic research (elucidating the molecular events underlying sarcoma development and progression) in order to establish improved diagnosis, prognosis and treatment for patients with bone and soft tissue tumors. One of his  major research interests are the lipomatous tumors, in particular the 'liposarcomagenesis', and pediatric sarcomas. 
Professor David Creytens and colleague pathologists of the Netherlands, Germany and USA were the first to describe 2 new morphological, immunohistochemical and molecular characterized lipomatous tumor entities (‘atypical spindle cell/pleomorphic lipomatous tumor’ and ‘myxoid pleomorphic liposarcoma’), which are now incorporated as new tumor entities in the 5th edition of the WHO Classification of Tumors Pathology and Genetics, 2020. Professor David Creytens has also contributed to several chapters of the new WHO Classification of Tumors Pathology and Genetics, 5th edition.


  • Master of Medicine (Catholic University Leuven, KUL, 2002)
  • Trainee in Pathology (2002-2007)
  • Fellow Surgical Pathology, NKI/Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam (The Netherlands) (2006, Dr. J. Peterse)
  • Fellow Bone and Soft Tissue Tumor pathology, Brigham and Women's Hospital, Harvard Medical School, Boston (USA) (Prof. dr. C.D.M. Fletcher, 2007)
  • Staff pathologist, Maastricht University Medical Center, Maastricht (The Netherlands) (2007-2009)
  • Senior staff pathologist, University Hospital Antwerp, Antwerp (UZA) (2009-2012)
  • Senior staff pathologist ('adjunct-kliniekhoofd'), Ghent University Hospital (UZ Gent, 2012-2014)
  • Senior staff pathologist ('kliniekhoofd', 'Head of Clinics'), Ghent University Hospital (UZ Gent, 2014-present)
  • Doctor in Medical Science: 'Clinicopathological, immunohistochemical and molecular characterization of lipomatous tumors: new pathologic insights and diagnostic tools (UGent, 2014)
  • Official Lecturer courses Soft Tissue Tumor Pathology, European School of Pathology (ESCOP) (2014-present)
  • Reviewer for Histopathology, Genes Chromosomes and Cancer, Journal of Clinical Pathology, Pathology, Virchows Archives, Laboratory Investigation, Human Pathology, Pathology Research and Practice, Journal of Cutaneous Pathology 

Research team

Contact & links

  • Department of Pathology, PAD Building, entrance 23, Ghent University Hospital, Corneel Heymanslaan 10, 9000 Ghent, Belgium
  • Prof. David Creytens is interested to receive invitations for talks or presentations
  • Cancer Centre
  • Member of the Consortium for Sarcoma Research Ghent (ConSaRGhent)

Key publications

  • Atypical pleomorphic lipomatous tumor: a clinicopathologic, immunohistochemical and molecular study of 21 cases emphasizing its relationship to atypical spindle cell lipomatous tumor. American Journal of Surgical Pathology, 2017. (PMID: 28877053)
  • Myxoid pleomorphic liposarcoma-a clinicopathologic, immunohistochemical, molecular genetic and epigenetic study of 12 cases, suggesting a possible relationship with conventional pleomorphic liposarcoma. Modern Pathology, 2021. (PMID: 34168281)
  • Atypical lipomatous tumour/well-differentiated liposarcoma and de-differentiated liposarcoma in patients aged ≤ 40 years: a study of 116 patients. Histopathology. 2019. (PMID: 31471922)
  • Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases. Acta Neuropathologica, 2021. (PMID: 33331994) 
  • Mutational analysis using Sanger and next generation sequencing in sporadic spindle cell hemangiomas. Genes Chromosomes and Cancer, 2017. (PMID: 28845522)
  • Soft tissue angiofibroma: clinicopathologic, immunohistochemical and molecular analysis of 14 cases. Genes Chromosomes and Cancer, 2017. (PMID: 28639284)
  • Myxoid liposarcoma of the foot: a study of 8 cases. Annals of Diagnostic Pathology, 2017. (PMID: 27806844)
  • CRISPR/Cas9 mediated knockout of rb1 and rbl1 leads to rapid and penetrant retinoblastoma development in Xenopus tropicalis. Science Reports, 2016. (PMID: 27739525)
  • The challenging differential diagnosis of skin tumours with a rhabdoid phenotype: not all tumours with rhabdoid phenotype belong to the group of SMARCB1-deficient tumours. Histopathology, 2016. (PMID: 26216536)
  • Atypical spindle cell lipoma: a clinicopathologic, immunohistochemical and molecular study emphasizing its relationship to classical spindle cell lipoma. Virchows Archives, 2014. (PMID: 24659226)
  • Array-based comparative genomic hybridization analysis of a pleomorphic myxoid liposarcoma. Journal of Clinical Pathology, 2014. (PMID: 24970901)
  • Presence of C11orf95-MKL2 fusion is a consistent finding in chondroid lipomas: a study of eight cases. Histopathology, 2013. (PMID: 23672313)
  • NR4A3 rearrangement reliably distinguishes between the clinicopathologically overlapping entities myoepithelial carcinoma of soft tissue and cellular extraskeletal myxoid chondrosarcoma. Virchows Archives, 2012. (PMID: 22569967)